CG Oncology (CGON) Financial Analysis & Valuation | Quarter Chart
CG Oncology (CGON)
CGONPrice: $73.73
Fair Value: 🔒
🔒score
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients wi... more
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a ... more
Description
Shares
| Market Cap | $6.50B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Arthur Kuan |
| IPO Date | 2024-01-25 | CAGR | -0.21% |
| Employees | 142 | Website | cgoncology.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
CGON chart loading...
Fundamentals
Technicals
| Enterprise Value | $6.74B | P/E Ratio | -31.64 |
| Forward P/E | -26.53 | PEG Ratio | — |
| P/S Ratio | 1527.28 | P/B Ratio | 6.79 |
| P/CF Ratio | -46.37 | P/FCF Ratio | -48.28 |
| EPS | $-2.33 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 666.01% | Gross Margin | -0.47% |
| Operating Margin | -42.39% | Profit Margin | -36.83% |
| ROE | -0.23% | ROA | -0.16% |
| ROCE | -0.2% | Current Ratio | 31.3 |
| Quick Ratio | 31.25 | Cash Ratio | 0.96 |
| Debt/Equity | 0.01 | Interest Coverage | — |
| Altman Z Score | 92.59 | Piotroski Score | 3 |